## MAILING CERTIFICATE

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to U.S. Patent and Trademark Office, Box Sequence, P.O. Box

2327, Arlington, VA 22202 on O

JUL 0 2 2002

Kay Bulen Print Name

IN THE COUTED STATES PATENT AND TRADEMARK OFFICE

Applicants: Nelson et al.

Filing Date: January 11, 2002

Serial No.: 10/044,070

For: PREVENTION OF CELL MIGRATION INITIATION WITH CMV US28 RECEPTOR

**ANTAGONISTS** 

Docket:

48892-1

Date:

June 26, 2002

Assistant Commissioner for Patents Washington, DC 20231

## STATEMENT UNDER 37 C.F.R. §1.821

Sir:

I hereby state that the content of the paper and computer-readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821, are the same.

Barry L. Davison

Attorney for Applicants Registration No. 47,309

ully submitted

Davis Wright Tremaine LLP 2600 Century Square 1501 Fourth Avenue Seattle, WA 98101-1688

Tel: 206-628-7621 Fax: 206-628-7699 Raw Sequence Listing Error Summary

ERROR DETECTED	SUCCESTED CORRECTION SERIAL NUMBER: 10/01/0
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE	
1 Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
3Misaligned Amino Numbering	The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s)contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section/that some may be missing.
6PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:  (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
8 Skipped Sequences (NEW RULES)	Sequence(s) missing. If Intentional, please insert the following lines for each skipped sequence. <110> sequence id number <400> sequence id number 000
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing.  Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
10Invalid <213> Response	Per 1.823 of Sequence Roles, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220><223> section is required when <213> response is Unknown or is Artificial Sequence
11Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.  Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or  "Unknown." Please explain source of genetic material in <220> to <223> section.  (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
12PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
13Misuse of n	n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

AMC/MH - Biotechnology Systems Branch - 08/21/2001





OIPE

RAW SEQUENCE LISTING

DATE: 01/30/2002 TIME: 15:47:35

PATENT APPLICATION: US/10/044,070

ION. 03/10/044,07

Input Set : A:\CONTSEQ.txt

Output Set: N:\CRF3\01302002\J044070.raw

```
Does Not Comply
      1 <110> APPLICANT: Nelson, Jay
                                                                   Corrected Diskette Needec
              Streblow, Daniel
              Soderberg-Naucler, Cecilia
      3
              Smith, Patricia
              Ruchti, Fronziska
      7 <120> TITLE OF INVENTION: Prevention of Cell Migration Initiation with CMV US28
Receptor Antagonists
      9 <130> FILE REFERENCE: 48892-1
     11 <140> CURRENT APPLICATION NUMBER: US/10/044,070
    13 <141> CURRENT FILING DATE: 2002-01-11
     13 <150> PRIOR APPLICATION NUMBER: US 09/387,044
     15 <151> PRIOR FILING DATE: 1999-08-31
     17 <150> PRIOR APPLICATION NUMBER: US 60/098,689
     19 <151> PRIOR FILING DATE: 1998-08-31
     21 <160> NUMBER OF SEO ID NOS: 28
     23 <170> SOFTWARE: Word
     25 <210> SEQ ID NO: 1
     27 <211> LENGTH: 1087
     29 <212> TYPE: DNA
     31 <213> ORGANISM: artificial sequence
                                                   De tem 11 on Eno Summary
caaaccggac 50 Sheet
     33 <220> FEATURE:
W--> 35 (223>) OTHER INFORMATION:
     35 <400> SEQUENCE: 1
    37 aaacgtcatc tcgccgacgt ggtgaaccgc tcatatagac caaaccggac
    39 gctgcctcag tctctcggtg cgtggaccag acggcgtcca tgcaccgagg
                                                                 100
                                                                 150
    41 gcagaactgg tgctatcatg acaccgacga cgacgaccgc ggaactcacg
    43 acggagtttg actacgatga agacgcgact ccttgtgttt tcaccgacgt
                                                                 200
    45 gcttaatcag tcaaagccag ttacgttgtt tctgtacggc gttgtctttc
                                                                 250
    47 tetteggtte categgeaac ttettggtga tetteaceat caeetggega
                                                                 300
    49 cgtcggattc aatgctccgg cgatgtttac tttatcaacc tcgcggccgc
                                                                 350
    51 cgatttgctt ttcgtttgta cactacctct.gtggatgcaa tacctcctag
    53 atcacaactc cctagccagc gtgccgtgta cgttactcac tgcctgtttc
    55 tacqtqqcta tqtttqccaq tttqtqtttt atcacqgaga ttqcactcga
                                                                 550
    57 tegetaetae getattgttt acatgagata teggeetgta aaacaggeet
    59 gccttttcag tattttttgg tggatctttg ccgtgatcat cgccattcca
                                                                 600
    61 cactttatgg tggtgaccaa aaaagacaat caatgtatga ccgactacga
                                                                 650
    63 ctacttagag gtcagttacc cgatcatcct caacgtagaa ctcatgcttg
                                                                 700
                                                                750
    65 gtgctttcgt gatcccgctc agtgttatca gctactgcta ctaccgcatt
                                                                 800
    67 tocaqaatoq ttqcqqtqtc tcaqtcqcqc cacaaaggtc gcattqtacq
    69 ggtacttata gcggtcgtgc ttgtctttat catcttttgg ctgccgtacc
                                                                850
    71 acctaacgct gtttgtggac acgttaaaac tcctcaaatg gatctccagc
    73 agctgcgagt tcgaaagatc gctcaaacgt gcgctcatct tgaccgagtc
                                                                950
    75 gctcgccttt tgtcactgtt gtctcaatcc gctgctgtac gtcttcgtgg 1000
```

77 gcaccaagtt teggcaagaa etacaetgte tgetggeega gtttegeeag 1050

RAW SEQUENCE LISTING DATE: 01/30/2002 PATENT APPLICATION: US/10/044,070 TIME: 15:47:35

Input Set : A:\CONTSEQ.txt

Output Set: N:\CRF3\01302002\J044070.raw

79 cgactctttt cccgcgatgt atcctggtac cacagca 81 <210> SEQ ID NO: 2 83 <211> LENGTH: 21 85 <212> TYPE: DNA 87 <213> ORGANISM: artificial sequence 89 <220> FEATURE: 91 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 93 <400> SEQUENCE: 2 95 cqqaattaqt caqtttcggt c 97 <210> SEQ ID NO: 3 99 <211> LENGTH: 20 101 <212> TYPE: DNA 103 <213> ORGANISM: artificial sequence 105 <220> FEATURE: 107 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 109 <400> SEQUENCE: 3 111 cgtcttgacc acgatagtac 20 113 <210> SEQ ID NO: 4 115 <211> LENGTH: 20 117 <212> TYPE: DNA 119 <213> ORGANISM: artificial sequence 121 <220> FEATURE: 123 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 125 <400> SEQUENCE: 4 127 gcagcctaag ttacgaggcc 129 <210> SEO ID NO: 5 131 <211> LENGTH: 20 133 <212> TYPE: DNA 135 <213> ORGANISM: artificial sequence 137 <220> FEATURE: 139 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 141 <400> SEQUENCE: 5 143 tagtgttgag ggatcggtcg 145 <210> SEQ ID NO: 6 147 <211> LENGTH: 20 149 <212> TYPE: DNA 151 <213> ORGANISM: artificial sequence 153 <220> FEATURE: 155 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 157 <400> SEQUENCE: 6 159 cgaattagtc agtttcggtc 161 <210> SEQ ID NO: 7 163 <211> LENGTH: 20 165 <212> TYPE: DNA 167 <213> ORGANISM: artificial sequence 169 <220> FEATURE: 171 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 173 <400> SEQUENCE: 7 175 agcgatgatg cgataacaaa 20

RAW SEQUENCE LISTING DATE: 01/30/2002 PATENT APPLICATION: US/10/044,070 TIME: 15:47:35

Input Set O A:\CONTSEQ.txt

Output Set: N:\CRF3\01302002\J044070.raw

.177 <210> SEQ ID NO: 8 179 <211> LENGTH: 20 181 <212> TYPE: DNA 183 <213> ORGANISM: artificial sequence 185 <220> FEATURE: 187 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 189 <400> SEQUENCE: 8 191 gtcaaatacc accactggtt 20 193 <210> SEQ ID NO: 9 195 <211> LENGTH: 18 197 <212> TYPE: DNA 199 <213> ORGANISM: artificial sequence 201 <220> FEATURE: 203 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 205 <400> SEQUENCE: 9 207 atttgtagag gtggtcat 209 <210> SEQ ID NO: 10 211 <211> LENGTH: 18 213 <212> TYPE: DNA 215 <213> ORGANISM: artificial sequence 217 <220> FEATURE: 219 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 221 <400> SEQUENCE: 10 223 gctcacctgc gttaaggt 18 225 <210> SEQ ID NO: 11 227 <211> LENGTH: 18 229 <212> TYPE: DNA 231 <213> ORGANISM: artificial sequence 233 <220> FEATURE: 235 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 237 <400> SEQUENCE: 11 18 239 gtgctgttta aggtgtgg 241 <210> SEQ ID NO: 12 243 <211> LENGTH: 18 245 <212> TYPE: DNA 247 <213> ORGANISM: artificial sequence 249 <220> FEATURE: 251 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 253 <400> SEQUENCE: 12 255 agtgtactcg aacaactg 18 257 <210> SEQ ID NO: 13 259 <211> LENGTH: 18 261 <212> TYPE: DNA 263 <213> ORGANISM: artificial sequence 265 <220> FEATURE: 267 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 269 <400> SEQUENCE: 13 271 caaccatacc ccgttggc 18

273 <210> SEQ ID NO: 14

RAW SEQUENCE LISTING DATE: 01/30/2002 PATENT APPLICATION: US/10/044,070 TIME: 15:47:36

Input Sets: A:\CONTSEQ.txt

Output: Set: N:\CRF3\01302002\J044070.raw

275 <211> LENGTH: 18 277 <212> TYPE: DNA 279 <213> ORGANISM: artificial sequence 281 <220> FEATURE: 283 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 285 <400> SEQUENCE: 14 18 287 ttcacqcagc aacaggcg-289 <210> SEO ID NO: 15 291 <211> LENGTH: 18 293 <212> TYPE: DNA 295 <213> ORGANISM: artificial sequence 297 <220> FEATURE: 299 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 301 <400> SEQUENCE: 15 303 cctggtaagg tatatcct 18 305 <210> SEQ ID NO: 16 307 <211> LENGTH: 18 309 <212> TYPE: DNA 311 <213> ORGANISM: artificial sequence 313 <220> FEATURE: 315 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 317 <400> SEQUENCE: 16 319 gtagctcaat atcaatgt 321 <210> SEQ ID NO: 17 323 <211> LENGTH: 18 325 <212> TYPE: DNA 327 <213> ORGANISM: artificial sequence 329 <220> FEATURE: 331 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 333 <400> SEQUENCE: 17 335 gcccttcttt gtatgtcc 337 <210> SEQ ID NO: 18 339 <211> LENGTH: 18 341 <212> TYPE: DNA 343 <213> ORGANISM: artificial sequence 345 <220> FEATURE: 347 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 349 <400> SEQUENCE: 18 351 atgggtacgt ttggtgtg 353 <210> SEQ ID NO: 19 355 <211> LENGTH: 18 357 <212> TYPE: DNA 359 <213> ORGANISM: artificial sequence 361 <220> FEATURE: 363 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 365 <400> SEQUENCE: 19 367 cgtcgtcgtc ggtgtcat 18

369 <210> SEQ ID NO: 20 371 <211> LENGTH: 18 RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/044,070
DATE: 01/30/2002
TIME: 15:47:36

Input Set : A:\CONTSEQ.txt

Output Set: N:\CRF3\01302002\J044070.raw

373 <212> TYPE: DNA 375 <213> ORGANISM: artificial sequence 377 <220> FEATURE: 379 <223> OTHER INFORMATION: US27 receptor-specific antisense oligonucleotide 381 <400> SEQUENCE: 20 18 383 cgtcgtgagt tccgcggt 385 <210> SEQ ID NO: 21 387 <211> LENGTH: 18 389 <212> TYPE: DNA 391 <213> ORGANISM: artificial sequence 393 <220> FEATURE: 395 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 397 <400> SEQUENCE: 21 18 399 cagggagtcg cttcatcg 401 <210> SEQ ID NO: 22 403 <211> LENGTH: 18 405 <212> TYPE: DNA 407 <213> ORGANISM: artificial sequence 409 <220> FEATURE: 411 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 413 <400> SEQUENCE: 22 415 tgattaagca cgtcggtg 18 417 <210> SEQ ID NO: 23 419 <211> LENGTH: 18 421 <212> TYPE: DNA 423 <213> ORGANISM: artificial sequence 425 <220> FEATURE: 427 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 429 <400> SEQUENCE: 23 431 gaagagaaag acaacgcc 18 433 <210> SEQ ID NO: 24 435 <211> LENGTH: 18 437 <212> TYPE: DNA 439 <213> ORGANISM: artificial sequence 441 <220> FEATURE: 443 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 445 <400> SEQUENCE: 24 18 447 gctgtggtac caggatac 449 <210> SEQ ID NO: 25 451 <211> LENGTH: 18 453 <212> TYPE: DNA 455 <213> ORGANISM: artificial sequence 457 <220> FEATURE: 459 <223> OTHER INFORMATION: US28 receptor-specific antisense oligonucleotide 461 <400> SEQUENCE: 25 463 ctccgacgcg aaaagctc 18

465 <210> SEQ ID NO: 26 467 <211> LENGTH: 18 469 <212> TYPE: DNA **VERIFICATION SUMMARY** 

DATE: 01/30/2002

PATENT APPLICATION: US/10/044,070

TIME: 15:47:37

Input Set : A:\CONTSEQ.txt

Output Set: N:\CRF3\01302002\J044070.raw

L:11 M:270 C: Current Application Number differs, Replaced Current Application Number

L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:35 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION: